British drugmaker GSK said on Thursday it would not be proceeding with regulatory submissions of its experimental treatment for moderate-to-severe rheumatoid arthritis (RA) after the drug failed to meet a key goal in a study.
https://www.pharmalive.com/wp-content/uploads/2022/10/ReutersGSK10-27-2022.webp7701200Reuters Healthhttps://www.pharmalive.com/wp-content/uploads/2020/01/Pharmalive_4c-300x37.pngReuters Health2022-10-27 02:13:102022-10-27 10:30:58GSK to skip regulatory submissions for experimental arthritis drug
